Bengalureans take a shine to anti-obesity drugs
Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...
Eli Lilly snaps six days of losses
Eli Lilly (LLY) shares snapped six straight days of losses as the stock closed 1.39% higher, at $812.76 on Friday. The ...
Donald Trump’s $1.4 trillion tariff threats scramble business plans, US companies form task-forces to tackle impact
Companies in the US, including Novo Nordisk, Boeing and Shein, are forming task forces to address the impact of Donald ...
Diabetes drug price war heats up, making treatment more affordable
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
The Business Times4d
Trump’s US$1.4 trillion tariff threat spurs companies to seek cover
PARIS] Ozempic-maker Novo Nordisk is planning to make more of its medicines for the US market in the country; Boeing risks a ...
Roche shares pop 4% on $5.3 billion obesity drug deal with Zealand Pharma
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Zealand ...
Unpacking the Latest Options Trading Trends in Eli Lilly
Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly plans to launch weight-loss drug in emerging markets this year
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug in major emerging markets like India, Brazil and ...
Eli Lilly plans launch of weight-loss drug in emerging markets in 2025, CFO says
Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday.